Sanzyme Biologics Pvt Ltd
- Home
- Companies
- Sanzyme Biologics Pvt Ltd
- Products
- Sanzyme - Model SNZ 1969 - Bacillus ...
Sanzyme - Model SNZ 1969 -Bacillus Coagulans
Our FDA GRAS approved flagship strain: Bacillus coagulans SNZ 1969™ is unique in the space of spore forming probiotic strains. It boasts an exceptional history of use, stability profile, research and genetic pedigree. Combined with Sanzyme’s experience in end-to-end production and decades of continuous technological improvement, SNZ 1969™ is a reliable, long term choice for inclusion in probiotic formulations in supplements, food, and pharmaceuticals.
Most popular related searches
Pedigree
- The technology for the production of SNZ 1969 and the mother culture was transferred via technology transfer by Sankyo Japan in 1972
- Strain was isolated from green malt and is a sister strain to the original Nakamura strain
History of Use
- SNZ 1969™ was produced and used by Sanzyme (then known as Uni-Sankyo) as the active ingredient in SPORLAC™, a pharmaceutical drug sold in the Indian pediatric market
- SPORLAC™ was launched in 1972 and is still being sold. It is the first probiotic to be sold in India and is still a market leader
- Over the years, products have been launched within the SPORLAC™ umbrella incluvding SPORLAC DS™, and SPORLAC PLUS™
- Over four decades in the Indian pharmaceutical market, there have been no reported serious adverse effects
- Unprecedented history of safe use: More than 2 Billion doses prescribed to infants, children, adults and elderly since 1992
End to End Production in a Dedicated Facility
- Sanzyme Biologics manages all inputs, and process parameters at all stages of probiotic production: from flasks to seed fermenters to full scale fermentation to blending and spray drying.
- Due to our years of experience in production of Bacillus coagulans, Sanzyme has made constant incremental improvements to the inputs used and production. The result is a healthier spore, and we test this against our stringent assay method.
Clinical REFERENCES DIGESTION DIARRHEA
- Clinical trial of Sporlac in gastroenteritis. 1999
Ronald Ross Institute of Tropical Diseases, Hyderabad. - Randomised controlled clinical trial of Lactobacillus sporogenes (Bacillus coagulans), used as probiotic in clinical practice, on acute watery diarrhoea in children.
Dutta P et al., Tropical Medicine and International Health 2011; volume 16 no 5, pp 555– 561. - Effect of Lactobacillus on the incidence and severity of acute rotavirus diarrhoea in infants.
A prospective placebo-controlled double-blind study
Chandra R.K., Nutrition Research 2002; 22: 65–69 - Sporlac in neonatal diarrhea
Dhongade R. K. and Anjaneyulu R., Maharashtra Medical Journal 1977; XXIII (II): 473
- Effect of Lactobacillus on the incidence and severity of acute rotavirus diarrhoea in infants.
A prospective placebo-controlled double-blind study
Chandra R.K., Nutrition Research 2002; 22: 65–69 - Sporlac in neonatal diarrhea
Dhongade R. K. and Anjaneyulu R., Maharashtra Medical Journal 1977; XXIII (II): 473
- A Study showing antagonistic effect of Lactobacilli casei and Lactobacilli sporogenesis against some common pathogens- in vitro.
Shukla P. and Sharma J., Int. J. Curr. Microbiol. App. Sci 2015; 4(6): 36-40 - A study on the antibiotic susceptibilities of some probiotic strains used as the dietary supplements.
Sharma J. and Shukla P., International Journal of Institutional Pharmacy and Life Sciences 2015; 5(5): September-October - Immunomodulatory activity of Lactobacillus sporogenes.
BABAR V., THOMAS R., BHASKAR M., International Journal of Therapeutic Applications 2012; Volume 3: 32 – 38 - Evaluating antimicrobial activity of common commercial Probiotic Products against Staphylococcus aureus
Sharma J. and Goyal A., Indian Res. J. Genet. & Biotech 2017; 9(2) May: 272 – 278
- A Study showing antagonistic effect of Lactobacilli casei and Lactobacilli sporogenesis against some common pathogens- in vitro.
Shukla P. and Sharma J., Int. J. Curr. Microbiol. App. Sci 2015; 4(6): 36-40
- Clinical trial of Sporlac in the treatment of recurrent Apthous ulceration
Sharma J. K. et al., U.P. State Dental Journal 1980; Vol 11 January: 7-12
- A comparative evaluation of probiotics on salivary mutans streptococci counts in Indian children
Jindal G et al., European Archives of Paediatric Dentistry 2011; 12: Issue 4
- Preliminary observations on effect of Lactobacllus sporogenes on serum lipid levels in hypercholerolemic patients
Mohan J. C. et al., Indian J Med Res (B) 1990; Vol 92 December: 431-432.